by Portfolio Grader | July 16, 2012 11:13 am
The overall ratings of seven Medical Devices stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
The rating of Synergetics USA (NASDAQ:SURG) slips from a C (“hold”) to a D (“sell”). Synergetics USA develops and manufactures medical devices and products for the hospital and healthcare communities. In Portfolio Grader’s specific subcategories of Earnings Momentum, Earnings Revisions, and Earnings Surprise, SURG also gets an F. For more information, get Portfolio Grader’s complete analysis of SURG stock.
Baxter International (NYSE:BAX) is having a rough week. The company’s rating falls from a C to a D rating. Baxter International develops, manufactures and markets products related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. For more information, get Portfolio Grader’s complete analysis of BAX stock.
Slipping from a C to a D rating, Meridian Bioscience (NASDAQ:VIVO) is taking a hit this week. Meridian Bioscience manufactures diagnostic test kits, bulk antigens, antibodies and bioresearch reagents used by researchers and other diagnostic manufacturers. As of July 16, 14.6% of outstanding Meridian Bioscience shares were held short. The stock has a trailing PE Ratio of 27. For more information, get Portfolio Grader’s complete analysis of VIVO stock.
This week, CryoLife (NYSE:CRY) drops from a C to a D rating. CryoLife preserves and distributes human tissues in addition to developing, manufacturing, and commercializing medical devices for cardiac and vascular transplant applications. For more information, get Portfolio Grader’s complete analysis of CRY stock.
Symmetry Medical (NYSE:SMA) earns a D this week, falling from last week’s grade of C. Symmetry Medical provides global orthopedic device manufacturers with implants and related instruments and cases. The stock gets F’s in Earnings Momentum and Margin Growth. The stock currently has a trailing PE Ratio of 137.5. For more information, get Portfolio Grader’s complete analysis of SMA stock.
Slipping from a C to a D rating, Derma Sciences (NASDAQ:DSCI) is taking a hit this week. Derma Sciences markets and sells a range of skin care, wound management, and specialty securement devices. The stock gets F’s in Earnings Revisions and Equity. For more information, get Portfolio Grader’s complete analysis of DSCI stock.
The rating of Accuray (NASDAQ:ARAY) declines this week from a C to a D. Accuray designs, develops, and sells medical radiation systems for the treatment of tumors anywhere in the body. The stock gets F’s in Equity, Cash Flow, and Margin Growth. As of July 16, 12% of outstanding Accuray shares were held short. For more information, get Portfolio Grader’s complete analysis of ARAY stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2012/07/7-medical-devices-stocks-to-sell-now-surg-bax-vivo/
Short URL: http://invstplc.com/1dcmuRu
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.